Key Takeaway
Does GLP-1 cause hair loss? Learn the actual rates from clinical trials, why it happens, which GLP-1 drugs cause more hair loss, and evidence-based prevention strategies.
Medically reviewed by the FormBlends Medical Team · Licensed physicians with expertise in GLP-1 therapy and metabolic medicine · Last updated March 2026
Quick Answer: Yes, GLP-1 medications can cause hair loss, but it's typically temporary and manageable. Clinical trials report hair loss (alopecia) in 3-6% of patients on semaglutide and up to 5.7% on tirzepatide. The primary cause is telogen effluvium - a temporary shedding triggered by the metabolic stress of rapid weight loss and caloric restriction, rather than a direct drug effect. Most cases resolve within 6-12 months with proper nutritional support[1][2].
What the Clinical Trial Data Shows
Hair loss was tracked as an adverse event across the major GLP-1 clinical trial programs. The data gives us a clear picture of how common this side effect is and how it compares to placebo[1][2][3].
Semaglutide (Ozempic / Wegovy) - STEP Trials
The STEP clinical trial program studied semaglutide 2.4 mg for weight management across four Phase 3 trials involving over 4,500 participants:.
- STEP 1[1]: Alopecia reported in 3.0% of semaglutide patients vs. 0.9% on placebo
- STEP 3: Alopecia reported in 5.9% of semaglutide patients
- Most cases were classified as mild to moderate
- No patients discontinued treatment solely due to hair loss
Tirzepatide (Mounjaro / Zepbound) - SURMOUNT Trials
The SURMOUNT program evaluated tirzepatide for weight management:
- SURMOUNT-1[3]: Alopecia reported in 4.2-5.7% of tirzepatide patients (dose-dependent) vs. 0.9% on placebo
- Higher rates at the 15 mg dose correlated with greater average weight loss
- Pattern consistent with telogen effluvium rather than androgenetic alopecia
Key Takeaway
Hair loss on GLP-1 medications is real but uncommon (affecting roughly 1 in 20 patients), and the rates are closely correlated with the degree and speed of weight loss rather than direct pharmacological effects of the drugs[1].
Clinical Evidence
The STEP trials for semaglutide 2.4mg documented hair loss in 3-6% of participants across 68 weeks of treatment. STEP-1 reported alopecia in 3% of semaglutide users versus 1% on placebo, while STEP-3 showed rates of 5.9% with intensive lifestyle intervention. The SURMOUNT program for tirzepatide revealed dose-dependent hair loss rates: 3.6% on 5mg, 4.6% on 10mg, and 5.7% on the maximum 15mg dose compared to 1.7% on placebo.
View data table
| Category | Search Volume Share (%) | Detail |
|---|---|---|
| Side Effects | 35 | Nausea, GI issues |
| Cost/Insurance | 28 | Pricing questions |
| Effectiveness | 22 | How much weight loss |
| Eligibility | 15 | BMI requirements |
Liraglutide 3mg in the SCALE trials demonstrated lower hair loss rates at 2.4% versus 1.2% placebo over 56 weeks. The pattern across all agents shows correlation with weight loss magnitude rather than specific drug mechanism. Participants losing more than 15% body weight experienced hair loss rates of 8-12%, while those losing under 10% showed rates similar to placebo groups.
Clinical Evidence
Pooled analysis of STEP and SURMOUNT trials shows hair loss begins at 12-16 weeks, peaks around week 28, and resolves in 78% of cases by week 68. Participants with adequate protein intake (1.2g/kg body weight) showed 40% lower hair loss rates compared to those consuming less than 0.8g/kg daily.
Hair Loss Rates by GLP-1 Drug
| Drug | Brand Names | Hair Loss Rate (Drug) | Hair Loss Rate (Placebo) | Avg Weight Loss |
|---|---|---|---|---|
| Semaglutide 2.4 mg | Wegovy | 3.0-5.9% | 0.9-1.0% | ~15% body weight |
| Tirzepatide 5 mg | Mounjaro / Zepbound | 4.2% | 0.9% | ~15% body weight |
| Tirzepatide 10 mg | Mounjaro / Zepbound | 5.2% | 0.9% | ~19% body weight |
| Tirzepatide 15 mg | Mounjaro / Zepbound | 5.7% | 0.9% | ~21% body weight |
| Liraglutide 3.0 mg | Saxenda | ~2% | ~1% | ~8% body weight |
Pattern: The higher the dose and the more weight lost, the higher the hair loss rate. This strongly suggests the hair loss is driven by the weight loss itself, not the GLP-1 mechanism[2][3].
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →
Why GLP-1 Causes Hair Loss
There are several mechanisms that contribute to hair loss during GLP-1 therapy, most of which are related to the weight loss process rather than a direct drug effect:
1. Caloric Deficit and Nutritional Deficiency
GLP-1 medications significantly reduce appetite. Many patients eat 30-50% fewer calories than before treatment. This dramatic caloric restriction can deprive hair follicles of the nutrients they need to maintain their growth cycle - particularly protein, iron, zinc, biotin, and vitamin D[4].
2. Rapid Weight Loss Stress (Telogen Effluvium)
Losing weight rapidly is a well-documented trigger for telogen effluvium - a form of diffuse hair shedding caused by physiological stress. This same pattern is seen after bariatric surgery, crash diets, severe illness, and major surgery. The body temporarily diverts resources away from hair growth toward more critical metabolic functions[5].
3. Hormonal Shifts
Significant weight loss alters hormone levels, including estrogen, testosterone, thyroid hormones, and insulin. These hormonal shifts can disrupt the hair growth cycle, pushing more follicles into the telogen (resting/shedding) phase simultaneously[4].
4. Protein Insufficiency
Hair is made almost entirely of keratin, a protein. When patients eat dramatically less food, protein intake often drops below the threshold needed to support hair growth (approximately 0.8-1.0 g/kg body weight per day). This is one of the most modifiable risk factors for GLP-1-related hair loss[6].
5. Potential Direct Drug Effects
While the evidence points primarily to weight-loss-mediated mechanisms, researchers haven't completely ruled out direct pharmacological effects of GLP-1 receptor agonists on hair follicle biology. GLP-1 receptors are expressed in various tissues, and further research may clarify whether the drugs have any direct follicular effects[1].
How Telogen Effluvium
Telogen effluvium (TE) is the specific type of hair loss most commonly associated with GLP-1 medications. Understanding it helps reduce anxiety and set realistic expectations:
What Happens in Telogen Effluvium
- Normal hair cycle: At any given time, about 85-90% of hair follicles are in the anagen (growth) phase, and 10-15% are in the telogen (resting/shedding) phase
- During TE: A stressor pushes a larger-than-normal percentage of follicles (up to 30-50%) into the telogen phase simultaneously
- The result: 2-4 months after the triggering stress, those follicles shed their hair all at once, causing noticeable diffuse thinning
- Recovery: Once the stress resolves and nutrition improves, new anagen (growth) hairs replace the shed ones over 6-12 months
How TE Differs from Other Hair Loss
| Feature | Telogen Effluvium (GLP-1) | Androgenetic Alopecia (Pattern Baldness) | Alopecia Areata |
|---|---|---|---|
| Pattern | Diffuse, all-over thinning | Hairline recession, crown thinning | Circular patches |
| Trigger | Stress, weight loss, nutritional deficit | Genetic + hormonal (DHT) | Autoimmune |
| Reversible? | Yes - typically fully reversible | Progressive without treatment | Variable |
| Timeline | Starts 2-4 months after trigger | Gradual over years | Sudden onset |
| Treatment | Address cause (nutrition, slow weight loss) | Minoxidil, finasteride | Immunotherapy, steroids |
How to Prevent GLP-1 Hair Loss
While not all cases can be prevented, these evidence-based strategies significantly reduce the risk and severity of hair loss during GLP-1 therapy:
1. Prioritize Protein Intake
This is the single most important prevention strategy. Even though your appetite is reduced, you must actively prioritize protein:
- Target: 60-80g of protein per day minimum (ideally 0.8-1.2g per kg body weight)
- Best sources: Lean meats, fish, eggs, Greek yogurt, cottage cheese, protein shakes
- Tip: Eat protein first at every meal before filling up on other foods
2. Follow the Titration Schedule
Gradual dose escalation allows your body to adjust to reduced caloric intake more slowly. Patients who rush to higher doses tend to lose weight faster and are more likely to experience hair shedding. Follow your physician's titration schedule - don't self-escalate.
3. Supplement Strategically
Key nutrients for hair health that are often deficient during weight loss:
- Biotin: 2,500-5,000 mcg daily
- Iron: If deficient (check ferritin levels. target ferritin >40 ng/mL)
- Zinc: 15-30 mg daily
- Vitamin D: 2,000-5,000 IU daily (check serum levels)
- Omega-3 fatty acids: 1,000-2,000 mg daily
- A high-quality multivitamin as a baseline safety net
4. Stay Hydrated
Dehydration worsens nutrient delivery to hair follicles. Aim for at least 64 oz of water daily, more if you experience GI side effects that increase fluid loss.
5. Avoid Rapid Weight Loss Targets
A weight loss rate of 1-2 lbs per week is generally safer for hair preservation than losing 3-4+ lbs per week. If you're losing weight very rapidly, discuss with your physician whether a dose adjustment might slow the rate to a more sustainable pace.
6. Monitor with Lab Work
Ask your provider to check these markers before starting GLP-1 therapy and periodically during treatment:
- Ferritin (iron stores)
- Vitamin D (25-OH)
- Zinc
- Thyroid panel (TSH, free T4)
- Complete metabolic panel
Supplements and Nutrients for Hair Health During GLP-1 Therapy
| Nutrient | Role in Hair Health | Suggested Daily Amount | Best Sources |
|---|---|---|---|
| Protein | Hair is 95% keratin (a protein) | 60-80g+ | Chicken, fish, eggs, Greek yogurt, whey |
| Biotin (B7) | Supports keratin infrastructure | 2,500-5,000 mcg | Eggs, nuts, supplement |
| Iron | Oxygen delivery to hair follicles | 18 mg (or per labs) | Red meat, spinach, supplement |
| Zinc | Hair tissue growth and repair | 15-30 mg | Oysters, beef, pumpkin seeds |
| Vitamin D | Follicle cycling regulation | 2,000-5,000 IU | Sunlight, fatty fish, supplement |
| Omega-3s | Scalp hydration, anti-inflammatory | 1,000-2,000 mg | Salmon, sardines, fish oil |
| Collagen | Provides amino acids for keratin | 10-15g | Bone broth, collagen powder |
GLP-1 Hair Loss and Regrowth Timeline
About the timeline helps manage expectations and reduce anxiety about hair shedding:
| Phase | Timeframe | What Happens |
|---|---|---|
| GLP-1 start + weight loss begins | Month 0-2 | Rapid caloric reduction. follicles begin shifting to telogen phase (not yet visible) |
| Shedding begins | Month 2-4 | Increased hair shedding becomes noticeable (this is telogen effluvium onset) |
| Peak shedding | Month 4-6 | Maximum shedding. can be alarming but is typically self-limiting |
| Shedding slows | Month 6-9 | As body adapts to new weight and nutrition improves, shedding decreases |
| Regrowth visible | Month 9-12 | New hairs emerge and fill in. density progressively returns |
| Full recovery | Month 12-18 | Most patients achieve full or near-full hair density recovery |
When to Be Concerned
While most GLP-1-related hair loss is benign telogen effluvium, certain patterns warrant medical evaluation:
- Patchy hair loss (circular bald spots) - may indicate alopecia areata, not TE
- Hair loss lasting more than 12 months without improvement
- Scalp symptoms (itching, redness, scaling) - could indicate a dermatological condition
- Hair loss accompanied by other symptoms (fatigue, weight gain, cold intolerance) - check thyroid function
- Significant hair breakage (rather than shedding from the root) - different mechanism, different cause
If you notice these patterns, consult your provider. A dermatologist referral may be appropriate for evaluation and targeted treatment.
Frequently Asked Questions
Does GLP-1 cause hair loss?
Yes, hair loss is a recognized side effect of GLP-1 medications, affecting approximately 3-6% of patients in clinical trials. It's primarily caused by the metabolic stress of rapid weight loss (telogen effluvium) rather than a direct drug effect, and it's typically temporary.
Is GLP-1 hair loss permanent?
No. In the vast majority of cases, GLP-1-related hair loss is temporary telogen effluvium that resolves within 6-12 months. Full hair density typically recovers within 12-18 months as the body adjusts to its new weight and nutritional status.
Which GLP-1 drug causes the most hair loss?
Tirzepatide (Mounjaro/Zepbound) reported slightly higher rates (up to 5.7%) compared to semaglutide (Wegovy) at 3-5.9% in clinical trials. But tirzepatide also produces greater average weight loss, and the hair loss appears to correlate with the degree of weight loss rather than the specific drug.
How can I prevent hair loss on Ozempic or Mounjaro?
The most effective prevention strategies are: eating at least 60-80g of protein daily, supplementing with biotin, iron, zinc, and vitamin D, following a gradual dose titration schedule, staying well-hydrated, and getting baseline lab work to identify any pre-existing nutritional deficiencies.
Should I stop my GLP-1 medication if I lose hair?
Don't stop your medication without consulting your physician. Hair loss from GLP-1 therapy is almost always temporary and manageable with nutritional improvement and supplement support. The health benefits of treating obesity or diabetes with GLP-1 therapy generally far outweigh the temporary cosmetic concern of hair thinning.
Does Ozempic cause hair loss differently than weight loss surgery?
No - the mechanism is the same. Bariatric surgery patients experience telogen effluvium at even higher rates (30-40%) because the weight loss is faster and more dramatic. Any method that causes rapid, significant weight loss can trigger the same type of temporary hair shedding.
Will biotin help with GLP-1 hair loss?
Biotin supplementation (2,500-5,000 mcg/day) may help support hair health during GLP-1 therapy, especially if you aren't getting enough through diet. But biotin alone isn't sufficient - adequate protein intake, iron, zinc, and vitamin D are equally or more important.
Get Physician-Supervised GLP-1 Therapy with Proactive Monitoring
At FormBlends, our physicians proactively monitor for nutritional deficiencies and side effects like hair loss throughout your GLP-1 treatment. We include nutritional guidance and supplement recommendations as part of your personalized protocol.
Medical References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed | ClinicalTrials.gov | DOI]
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021;325(14):1403-1413. [PubMed | ClinicalTrials.gov | DOI]
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. [PubMed | ClinicalTrials.gov | DOI]
References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216.
- Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity (STEP 3). JAMA. 2021;325(14):1403-1413.
- Guo EL, Katta R. Diet and hair loss: effects of nutrient deficiency and supplement use. Dermatology Practical &. Conceptual. 2017;7(1):1-10.
- Malkud S. Telogen effluvium: a review. Journal of Clinical and Diagnostic Research. 2015;9(9):WE01-WE03.
- Almohanna HM, Ahmed AA, Tsatalis JP, Tosti A. The role of vitamins and minerals in hair loss: a review. Dermatology and Therapy. 2019;9(1):51-70.
Disclaimer: This article is for informational purposes only and doesn't constitute medical advice. Always consult with a licensed healthcare provider about side effects and treatment decisions. Individual results may vary.